Signaling through FGF receptors, which constitute a family of membrane-spanning tyrosine kinases, can stimulate cell proliferation, induce or inhibit cell dierentiation and plays an important role in development. Recently, mutations in FGF receptors have been shown to be associated with a number of genetically dominant human skeletal disorders. A remarkably conserved mutation (Gly 380?Arg) in the transmembrane region of FGFR-3 has been shown to be responsible for achondroplasia (ACH) but it was not clear whether such mutations result in loss of receptor function or constitutive activation. We have therefore made mutations in the transmembrane regions of murine FGFR-2 and FGFR-3 and studied their eect on receptor activity. We show here that the ACH mutation in FGFR-3 as well as two similar mutations in FGFR-2 result in constitutive activation of these receptors. This is manifested in their ability to become autophosphorylated in the absence of ligand in L6 cells, transforming activity on NIH3T3 ®broblasts, and the ability to inhibit myogenic dierentiation in the absence of growth factor. Thus the transmembrane region of FGFR-2 and FGFR-3 plays a regulatory role in receptor function and the ACH mutation produces a dominant oversignaling receptor which is no longer regulated by FGF binding. These ®ndings also support the newly identi®ed role of FGF signaling as a negative regulator of bone growth.
Introduction
Receptor tyrosine kinases (RTK) represent a large class of transmembrane proteins whose function is the transmission of a proliferative or dierentiation signal initiated by the binding of a speci®c ligand to the extracellular portion of the receptor. The major eect of such binding is to induce or stabilize receptor dimerization, which results in autophosphorylation of tyrosine residues in the intracellular domain of the molecule. Association with various substrates and adaptors and activation of the signal transduction cascade(s) characteristic of each receptor follows, eventually inducing speci®c expression of genes whose products are involved in cell proliferation or differentiation (Schlessinger and Ullrich, 1992; Lemmon and Schlessinger, 1994) . In contrast to this ligand regulated action, receptors can be found in a constitutively activated form, which is independent of ligand binding. Such activated receptors often manifest themselves as oncogenes, as they can cause uncontrolled signaling and cell proliferation, and it is generally assumed that activation results from a shift of RTK equilibrium towards a dimeric state, in the absence of a ligand (Bargmann et al., 1986; Stern et al., 1988; Sternberg and Gullick, 1989; Lonardo et al., 1990; Cheatham et al., 1993; Lemmon and Schlessinger, 1994) . Although the manifestation of a constitutively activated receptor as an oncogene has been recognized for some time, it is quite likely that such molecules could have profound eects on other processes, such as dierentiation and development.
The FGF family of growth factors includes nine distinct but homologous polypeptides which can stimulate the proliferation of a wide variety of cells and also exhibit potent neurotrophic and angiogenic activities. FGFs can also induce dierentiation of certain cell types or inhibit dierentiation (e.g. of myoblasts into myotubes) Mason, 1994) . The action of FGFs is mediated by their interaction with high anity RTKs. The FGF receptors (FGFR) also constitute a gene family, which so far includes four members. Binding of FGFs to their receptors exhibits only partial speci®city, and thus a given receptor can often bind and be activated by a number of ligands with reasonable eciency (Mansukhani et al., 1992; Johnson and Williams, 1993) . The implications of this complex hierarchy of receptor binding anities are not yet understood.
Several lines of evidence indicate that FGF signaling plays a major role in development. FGF signaling has been shown to be important for mesoderm induction in Xenopus (Amaya et al., 1991 (Amaya et al., , 1993 . Developmental abnormalities are associated with knock-out of the FGF-4 and FGF-3 genes as well as of FGFR-1 (Mansour et al., 1993; Deng et al., 1994; Yamaguchi et al., 1994; Feldman et al., 1995) and targeting of dominant-negative receptor molecules to various organs in transgenic mice also results in a variety of defects in development Peters et al., 1994; Mima et al., 1995; Campochiaro et al., 1996) . A remarkably conserved mutation at a guanosine nucleotide at position 1138 of FGFR-3 has been shown to be associated with achondroplasia (ACH), a human autosomal dominant trait whose classic features include rhizomelic dwar®sm, macrocephaly and other skeletal abnormalities (Rousseau et al., 1994; Shiang et al., 1994) . This mutation substitutes Gly 380 with Arg in the transmembrane region of the receptor. Furthermore, other genetic syndromes leading to human skeletal disorders have been linked to mutations in FGFR-1, FGFR-2 and FGFR-3 (Muenke and Schell, 1995) . It was not clear however whether such mutated receptors would be endowed with loss of function, or, more likely in view of the dominant transmission of these traits, a dominant-negative or constitutively activated phenotype. The ACH mutation in FGFR-3 is reminiscent of the oncogenic activation of neu (HER-II), which is due to a Val?Glu mutation in the transmembrane domain and results in constitutive activation independent of ligand binding (Bargmann et al., 1986; Segatto et al., 1988; Wides et al., 1990; Miloso et al., 1995) . This mutation is proposed to stabilize the dimeric conformation of the receptor due to inter-receptor bond formation (Sternberg and Gullick, 1989) . The neu mutation and the ACH mutation in FGFR-3 both aect the transmembrane region of the receptor, suggesting the possibility that the ACH mutation in FGFR-3 and analogous mutations in other FGF receptors could have an activating eect. We have therefore studied the eects of amino acid substitutions in the transmembrane region of FGFR-2 and 3 on receptor function.
The results presented in this report show that the ACH mutation in FGFR-3 as well as mutations in the transmembrane region of FGFR-2, two of which are positionally homologous to the receptor 3 mutation, produce constitutively activated receptors which show autophosphorylation in the absence of ligand. Two of the FGFR-2 mutants can transform NIH3T3 cells, while the FGFR-3 mutant was only slightly active in this assay. All of the receptor mutants tested are able to inhibit myoblast dierentiation in the absence of exogenous FGF. Thus the transmembrane region of FGF receptors plays a regulatory role in receptor function, and the ACH mutation produces a dominant oversignaling receptor which is no longer regulated by FGF binding.
Results
To determine the eects of mutations in the transmembrane region of FGF receptors on receptor function, we created three mutations in the transmembrane region of murine FGFR-2 and one in murine FGFR-3 by site-directed mutagenesis. The ®rst FGFR-2 mutation replaces the cysteine at position 382 with arginine (C382R), the second the same cysteine with aspartic acid (C382D) and the third the valine at position 392 with arginine (V392R). The mutation in FGFR-3 replaces the glycine at position 374 with arginine equivalent to the G380R achondroplasia mutation and will be referred to as G380R. Figure 1 shows that the transmembrane region of human and murine FGFR-2 and -3 are almost identical in amino acid sequence, thus likely to be structurally and functionally conserved. It can also be seen that the transmembrane region of FGFR-2 and -3 are partially conserved. In particular, valine 392 of FGFR-2 is conserved in both receptors, while the glycine at positon 380 of FGFR-3 is replaced by a cysteine (position 382) in FGFR-2. The mutant cDNAs were cloned in CMV-driven expression vectors and their activity was compared to that of wild-type receptors 2 and 3, and also to two mutants of receptor 2 which are kinase negative because of a mutation in the ATP binding domain (R2/ATP 7 ), or incapable of transphosphorylation because of truncation of the C-terminal portion of the receptor (R2/stop).
Expression and phosphorylation of mutant transmembrane receptors PRK-5 derived plasmids encoding the mutant and wild-type receptors were transiently transfected into human 293 cells. Cell extracts were immunoprecipitated and incubated with [ 32 P]gATP to determine in vitro kinase activity, or blotted with an antibody directed against the extracellular portion of the receptor to determine their level of expression ( Figure 2 ). All FGFR-2 mutants were expressed at lower levels than the wild type ( Figure 2b ). The dierence in the levels of expression was somewhat variable from experiment to experiment, ranging from two to fourfold. In contrast, the receptor 3 mutant was expressed at levels similar or slightly higher than its wild type control (Figure 2b ). When the dierences in expression levels are taken into account, it appears that the tyrosine kinase activity in vitro of all mutants was similar to that of their wild-type counterparts (Figure 2a ), although the kinase activity of FGFR-3 was signi®cantly lower than that of FGFR-2. The weak kinase activity of FGFR-3 has been previously observed (Ornitz and Leder, 1992; Chellaiah et al., 1994; Wang et al., 1994) .
In similar experiments, the same CMV driven constructs were transiently transfected into 293 or Cos cells and the levels of receptor phosphorylation in vivo were determined by immunoprecipitation with anti-receptor antibodies followed by Western blotting with anti-phosphotyrosine antibodies (Figure 2c ). Transient transfection of FGF receptors into 293 or Cos cells results in very high levels of expression per transfected cell. Consequently, receptors become autophosphorylated to a considerable extent even in the absence of ligand, presumably due to high levels of spontaneous dimerization as has been observed previously (Mathews and Vale, 1993; Chen and Weinberg, 1995) .
The results shown in Figure 2c indicate that all FGFR-2 transmembrane mutants exhibit signi®cant phosphorylation. Exposure of transfected 293 cells to acidic FGF (FGF-1) which binds FGFR-2 and -3 with similar anities had no signi®cant eect on the degree of receptor phosphorylation, indicating that the extent of dimerization was saturated in these particular experiments. In cells transfected with FGFR-3, although, as observed in the previous experiment, phosphorylation was weaker than with FGFR-2, both mutant and wild type receptors also appear to be equally phosphorylated ( Figure 2d ). As expected, the C-terminal deletion mutant showed no detectable phosphorylation, in vitro or in vivo, and the same was true of the kinase negative mutant (Figure 2a ± c) . Taken together, the results of the in vitro kinase activity and of the in vivo phosphorylation experiments clearly indicate that the transmembrane FGFR-2 and FGFR-3 mutations do not result in loss of function, whether of a recessive or dominant type and suggested that these mutations could lead to constitutive activation.
Receptor phosphorylation in stably transfected L6 cells
To determine whether the transmembrane mutant receptors were constitutively activated under physiological conditions, we expressed these receptors in L6 rat cells, which are essentially FGF receptor-negative, selected stable transfectants and studied the ability of the mutated receptors to bind and to be activated by FGFs.
Cells were co-transfected with pMJ30 plasmids encoding mutated and wild-type receptors together with a selectable marker encoding G418 resistance. Several G418 resistant clones were isolated and analysed for receptor mRNA expression and number of FGF binding sites. A number of clones expressing similar numbers (30 ± 60 000) of FGF binding sites were further analysed for their response to FGFs. Figure 3 shows experiments of immunoprecipitation followed by Western blot with anti-phosphotyrosine antibodies on cells expressing wild-type and mutated FGFR-2 receptors. In the wild-type expressing cells, following serum starvation, the receptor was not phosphorylated but phosphorylation became evident after treatment of the cells with FGF-1, reaching a maximum at a concentration of about 20 ng/ml. Phosphorylation of a putative FGFR substrate of * 90 KDa (Coughlin et al., 1988; Mansukhani et al., 1990) could also be detected ( Figure 3a ). In contrast a representative clone expressing the C382R mutant of FGFR-2 showed a high degree of phosphorylation of both the receptor and the 90 KDa protein in the absence of FGF stimulation ( Figure 3a) . Similar results were observed with L6 cells expressing the V392R FGFR-2 mutation (Figure 3b ). In contrast, the cells expressing the C382D mutant receptor behaved similarly to the wild-type (not shown).
In the case of FGFR-3 and its mutated version, although its degree of phosphorylation is generally much lower and indeed FGFR-3 appears to be à weak' receptor, at least in ®broblasts, a similar eect can be observed. Phosphorylation of the wild type receptor is undetectable in the absence of ligand and increases slightly upon treatment with FGF-1, while the mutated receptor becomes phosphorylated to a much higher degree, in the presence of FGF ( Figure  3c ). To con®rm these conclusions we examined a large number of FGFR-3 expressing L6 clones. Three wildtype and three mutant expressing clones are shown in Figure 3d . It can be seen that all mutant expressing clones exhibit a high degree of receptor phosphorylation in the presence of FGF-1 and a degree of phosphorylation can be observed also in the absence of ligand, while in the three clones expressing wild-type FGFR-3 phosphorylation is barely detectable even after FGF stimulation. Thus these experiments indicate that FGFR-2 mutants C382R and V392R behave as constitutively activated receptors, and the same is true of the FGFR-3 mutant. 
Mutated receptors can transform NIH3T3 cells
To further verify the hypothesis that the transmembrane mutations described above resulted in constitutive activation of FGF-receptors, plasmids expressing mutated and wild-type receptors were transfected into NIH3T3 cells. We reasoned that constitutively activated receptors should be oncogenic and capable of inducing transformation in these cells, as has been shown for other`activated' receptors (Stern et al., 1988; Lonardo et al., 1990; Cheatham et al., 1993) . The results of this experiment are shown in Table 1 . It can be seen that FGFR-2 mutants C382R and V392R are capable of transforming NIH3T3 cells with good eciency, while mutant C382D did not induce transformation, in line with the results described in the preceding section.
In the case of FGFR-3, we could not detect obvious transformation either with mutant or with wild-type plasmids. The weak kinase activity of these receptors could not have generated enough signaling to produce morphological transformation. We therefore selected colonies expressing similar levels of wildtype and mutated FGFR-3 as detected by Northern analysis and exposed them to increasing concentrations of FGF-1. Figure 4 shows the result of such an experiment for two mutant and one wild-type FGFR- 
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NIH3T3 cells were transfected with pRK5 vectors expressing the indicated DNAs (5 mg/plate) along with a G418 resistance-encoding plasmid (0.5 mg). Each transfection was divided into four 10 cm plates and the cells incubated in the presence of G418 (400 mg/ml) for 2 weeks. The number of total colonies and morphologically transformed colonies was counted after ®xing and staining. A plasmid expressing FGF-4 (K-FGF) was used as a positive control (Talarico and Basilico, 1991) 3 clones. It can be seen that the morphology of the mutant FGFR-3 expressing cells is slightly more transformed than that of the wild-type even in the absence of exogenous FGF, as revealed by their more refractile and spindle-like appearance. This dierence is considerably emphasized in the presence of 0.5 ng/ ml of FGF-1. Much higher concentrations of FGF-1 were required to achieve the same morphological changes in cells expressing wild-type FGFR-3 (Figure 4 ). We therefore conclude that NIH3T3 cells expressing the Gly380-Arg mutant of FGFR-3, although not frankly transformed, are much more susceptible to the action of FGF than cells expressing the wild-type receptor, most likely because the mutant receptor equilibrium is already shifted towards a dimeric state. NIH3T3 cells transformed by growth factorencoding oncogenes can grow in serum-free medium because of an autocrine growth loop provided by the constitutive expression and secretion of the growth factor. If the cells transformed by the FGFR-2 mutants owed their phenotype to intrinsic activation of FGF signaling, they would be expected to also grow in serum-free medium. In untransfected
FGF-1 0.5 ng/ ml FGF-1 5 ng/ ml Figure 4 Morphological transformation of NIH3T3 clones expressing wild-type FGFR-3 or mutant R3/G380R (clones (E) and (H)). NIH3T3 clones were starved for 48 h in DMEM plus 0.5% calf serum and treated with increasing concentrations of FGF-1 in the presence of 25 m/ml heparin for 24 h. Cells were ®xed in formalin and stained with crystal violet NIH3T3 cells that express endogenous FGFR-1 and FGFR-2 (Li et al., 1994) , DNA synthesis dropped sharply in serum-free medium, while the cells expressing the mutated receptors, R2/C382R and R2/V392R, DNA synthesis was only slightly reduced, re¯ecting the continued proliferation of these cells in serum-free medium (data not shown).
FGFR-2 and FGFR-3 transmembrane mutants inhibit myoblast dierentiation
FGFs are known to inhibit the dierentiation of myoblasts in culture in the absence of serum factors (Spizz et al., 1986; Fox et al., 1994) . We therefore expected that our FGFR mutants could have been capable of inhibiting myoblasts dierentiation when expressed in such cells even in the absence of a ligand. To verify whether this hypothesis was correct, we transfected mutant and wild-type receptors into the C2-7 myoblast cell line, selected pools of colonies expressing these receptors and exposed them to conditions known to induce dierentiation (0.5% horse serum) in the presence or absence of increasing concentrations of FGF-1. We then monitored differentiation by observing characteristic phenotypic changes (i.e. myotube formation) and the appearance of the dierentiation-speci®c marker, myosin heavy chain (Table 2 and Figure 5 ).
As expected, FGF-1 inhibited dierentiation in the parental as well as in the transfected cells. Cells transfected with wild-type receptors showed slightly reduced dierentiation when compared to the parental cells (Table 2) , probably because of increased expression of FGF receptors on their surface. Cells expressing FGFR-2 mutants C382R and V392R were however completely resistant to dierentiation and the same eect was observed with the FGFR-3 G380R mutant, even though this mutant was not capable of transformation of NIH3T3 cells. FGFR-2 mutant C382D, which also could not transform NIH3T3 cells, was capable of inhibiting dierentiation, although to a lesser extent. We conclude from these experiments that all our FGFR mutants behaved as constitutively activated in myoblasts, and that apparently the dierentiation-inhibiting phenotype is more easily detectable than the ability to cause oncogenic transformation, perhaps because lower degrees of FGF signaling are required to inhibit dierentiation.
Discussion
The results presented in this report show that mutations in the transmembrane region of FGFR-2 and -3 can lead to constitutive activation of these receptors, which exhibit autophosphorylation in the absence of ligand, can transform NIH3T3 cells, and inhibit dierentiation of myoblasts. While the original stimulus for this investigation resulted from the ®nding of a remarkably conserved mutation (Gly 380?Arg) in the FGFR-3 transmembrane region in ACH (Rousseau et al., 1994; Shiang et al., 1994) , we were interested in extending these studies to another FGF receptor, namely FGFR-2 mainly for the following reasons: (1) to ascertain whether the eect of similar mutations resulted in the same phenotype in two of the FGF receptors; (2) because other mutations associated with dominant skeletal disorders had been detected in FGFR-2 (Muenke and Schell, 1995) ; (3) to overcome the problems associated with studying changes in thè weak' signaling potential of FGFR-3. As observed by others (Ornitz and Leder, 1992; Chellaiah et al., 1994; Wang et al., 1994) , this receptor seems to posssess a weak kinase activity, and is unable to generate a strong mitogenic signal when expressed in receptor-negative cells. While it is quite possible that the apparent weakness of this receptor depends on the environment in which it is expressed, and that its signaling would be much stronger when expressed in the appropriate host cell (e.g. chondrocytes), we thought that results obtained with FGFR-2 would have complemented and extended those obtained with FGFR-3.
We studied the eects of the ACH mutation in FGFR-3 as well as that of replacing the positionally equivalent cysteine in FGFR-2 with arginine or aspartic acid, and the conserved valine at position 392 with arginine. All of these mutations did not impair in vitro or in vivo kinase activity, showing that they did not lead to loss of function. Transfection into L6 rat cells showed clearly that the C382R and the V392R mutants of FGFR-2 were constitutively activated even in the absence of a ligand. The results obtained with FGFR-3 were less striking, but also indicated that the ACH mutation resulted in higher levels of activity than that of the wild-type. Activated receptors can be oncogenic and thus it was not surprising that the C382R and V392R mutants of FGFR-2 were capable of transforming NIH3T3 cells. The FGFR-3 G380R mutant did not score in this assay, but cells expressing this receptor appeared to respond to lower concentrations of FGF-1 with typical morphological changes than that required by cells expressing the wild-type receptor. Since the binding anities of FGFR-3 and of its G380R mutant for FGF-1 are approximately the same (data not shown), this indicates that the equilibrium of the ACH receptor is probably shifted toward a dimeric state, thus requiring lower concentrations of ligand to be induced to signal. Somewhat surprising results were obtained when these receptors were expressed in C2-7 myoblasts. In this context all receptor mutants inhibited differ- 2.8 51 ± ± ± ± ± *C2-7 cells as well as C2-7 cells stably transfected with pRK-5 plasmids encoding mutated and wild-type FGF receptors were plated in 24 wells plates at 50 000 cells/well. Twenty-four hours later they were incubated in dierentiation medium (DMEM+0.5% horse serum) in the presence or absence of FGF-1 (ng/ml). Cells were ®xed and stained with Giemsa 96 h later.
a Determined by counting the number of polynucleated myotubes/microscopic ®eld. C2-7 cells in the absence of FGF-1(7) were used as the control. Numbers in control C2-7 cultures correspond to about 60% of the cells being dierentiated myotubes entiation, including the C382D mutant of FGFR-2 which was not capable of transformation of NIH3T3 cells, and the FGFR-3 ACH mutant, whose activity in the NIH3T3 assay was low, and did not show strong autophosphorylation in L6 cells. C2-7 cells did not express very high amounts of receptor as compared to the other cells studied. The number of endogenous FGF-1 binding sites is about 10 000/cell and was increased to approximately 20 000 in the transfectants (data not shown). We therefore interpret these results as indicating that even a relatively low degree of receptor activation is sucient to inhibit dierentiation in this system, thus indicating that all mutants studied exhibit some degree of constitutive activation.
While this manuscript was in preparation, a report by Webster and Donaghue (1996) was published, which also studied the properties of the FGFR-3 ACH mutation. To obviate the weak signaling of FGFR-3 Figure 5 Inhibition of C2-7 cell dierentiation. Wild-type and mutant FGFR-2 and FGFR-3 constructs in pRK5 vector were transfected into C2-7 myoblast cells. Receptor-expressing clones were plated into 24 well plates at a density of 50 000 cells/well. 24 h later, cells were incubated in DMEM containing 0.5% horse serum to induce dierentiation. Cells were ®xed and stained after 96 h. discussed above, these authors constructed chimeric receptors in which the transmembrane portion of the neu receptor was replaced by that of human FGFR-3 or of its ACH mutant. The transmembrane region of the ACH mutant was capable of activating neu transforming potential, while that of wild-type FGFR-3 did not. These results also led to the conclusion that the ACH mutation results in constitutive activation.
While it is clear that transmembrane region mutations in FGF receptors can result in activation, probably by promoting receptor dimerization, the precise mechanism by which this occurs is still unclear. Previous studies on the activated neu receptor implicated the transmembrane region in receptor dimerization. It has been proposed that the amino acids in the transmembrane region form an a-helical structure. Introduction of a protonated glutamic acid residue in place of valine 664 in the neu receptor is proposed to facilitate hydrogen-bonding between adjacent a-helices, thus leading to enhanced receptor dimerization. From the comparison of many transmembrane domains Sternberg and Gullick (1989) delineated a conserved pentapeptide sequence that is required for maintaining the a-helical structure. This pentapeptide is not conserved in FGFR-2 and only partially conserved in FGFR-3. Our attempts to demonstrate enhanced dimerization in the mutant receptor expressing cells were inconclusive, probably due to the ineciency of the crosslinking agent and to the low level of receptor expression. Thus how the transmembrane region mediates dimerization remains to be elucidated.
The results presented here also have signi®cant implications with respect to the role of FGFs in bone dierentiation and development. It appears that the ACH mutation and similar mutations in FGFR-2 induce constitutive activation of these receptors. It is therefore clear that ACH does not result from the lack of FGF signaling, but rather by unregulated signaling. FGFR-3 is expressed in the embryos primarily in prebone cartilage and in the nervous system, and after birth in the proliferating chondrocytes . The ACH defect is particularly apparent in the long bones, and result in defective growth plate formation with abnormal endochondral ossi®cation and thus shortening of the limbs (Iannotti et al., 1994; Erlebacher et al., 1995) . The excessive FGF signaling in ACH chondrocytes would lead to perturbation of growth plate formation, perhaps resulting in an improper temporal and spatial dierentiation. In this respect the very recent results of Deng et al. (1996) and Colvin et al. (1996) are particularly interesting. These authors knocked-out the FGFR-3 gene in mice and observed that mice with homozygous FGFR-3 deletions exhibit overgrown long bones and abnormal curvature of the spine and tail. The long bone growth plates of these animals are hypertrophic with an increase in mitotic activity in proliferating chondrocytes, and enhanced deposition of osteoblasts and osteoclasts. Taken together these results could suggest that FGF signaling negatively regulates chondrocyte proliferation and dierentiation. The available data however do not completely rule out an alternative hypothesis, i.e. that excessive FGF signaling causes accelerated dierentiation of chondrocytes with premature bone formation, as this would also result in defective bone growth, although FGF-2 has been shown to inhibit chondrocyte terminal dierentiation in culture (Kato and Iwamoto, 1990) .
While these reports clearly implicate unregulated FGF signaling in abnormal endochondrial bone formation, the precise relationship between altered receptor function and the process of bone formation during development and growth remains to be elucidated. These results however make it tempting to speculate on why ACH, while frequently sporadic, is associated only with a speci®c amino acid change in FGFR-3. It is quite possible that similar activating mutations could occur in other residues in the transmembrane region, but that their eect could be too strong to be compatible with survival. It is worth noting that although ACH is dominant, the homozygous mutation is generally lethal at or shortly after birth (Stanescu et al., 1990) and that FGFR-3, although predominantly expressed in the cartilage of long bones, is also expressed in other organs. It is quite possible that while subtle activating eects are compatible with survival, stronger eects would not be, and thus often be undetected. In conclusion, the results presented in this report show that mutations in the transmembrane domain of FGFR-2 and -3 can lead to constitutive receptor activation and unregulated signaling, and that unregulated signaling is likely to be responsible for ACH and possibly other skeletal disorders involving FGF receptors. The precise mechanism by which FGF signaling regulates orderly and harmonious bone formation remains to be elucidated.
Materials and methods

FGFR-2 and FGFR-3 constructs
The Transformer TM Site-Directed Mutagenesis Kit (Clontech Labs) was used to create single amino acid substitutions in the transmembrane domain of FGFR-2 and FGFR-3. A 3.4 kb cDNA encoding the murine FGFR-2 in pUC19 (NarI ± HindIII) (Mansukhani et al., 1992 ) and a 4.1 kb cDNA for FGFR-3 (HindIII ± XbaI) (Ornitz and Leder, 1992) were used as templates. The mutagenic primers were designed with 10 ± 15 bases of homology on either side of the mismatch. The primers used for FGFR -2 were: 5' -GACCCCTATGCGGTAAAATAG-CTATCTCC-3' (C382R) 5'-GACCCCTATGTCGTAAA-ATAGCTATCTCC-3' (C382D) and 5'-GACTAGTCACC-CGCATGCAGGCG-3' (V392R). The primer for FGFR-3 was 5' -GGAAGAAGACCACCCGGTAGCTGAGG -3' (G374R). The transmembrane regions were con®rmed by sequencing and the cDNAs were subcloned in to the CMVdriven expression vectors pMJ30 and pRK5.
Transfections
Cells were plated at a density of 5610 6 cells in 10 cm plates in DMEM containing 10% fetal calf serum. Transfection of cells was carried out with 10 mg of plasmid DNA encoding each expression construct using calcium phosphate precipitation. Cells were washed after overnight transfection split 1:10 and selected in medium containing G418.
In vitro kinase assay 293 or Cos cells were transfected with each construct as described above. After 48 h cells were lysed with lysis buer (20 mM HEPES pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA) containing protease inhibitors, [aprotinin 10 mg/ml; leupeptin 2 mg/ml; PMSF 1 mM] and incubated with antibodies coupled to protein A-Sepharose (anti-FGFR-2 polyclonal antibodies from Dr I Lax, NYU Medical Center and anti-FGFR-3 antibodies were from Santa Cruz Biotech and Dr D Ornitz, Washington State University, St Louis). The immunoprecipitates were washed with HNTG buer (20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol) and subjected to an in vitro kinase reaction in HNTG containing 10 mM MnCl 2 , 5 mM MgCl 2 and 12.5 mCi of [g-32 P]ATP (speci®c activity 3000 mCi/mmol) at 378C for 30 min. The reaction was stopped by the addition of sample buer and boiled for 5 min. Samples were run on a 7.5% SDS ± PAGE and the phosphorylated proteins visualized by autoradiography.
In vivo receptor phosphorylation
Stably transfected L6 cell lines expressing the wild-type and mutant FGFR in pMJ30 vector were maintained in medium containing 250 mg/ml G418. Cells were washed once with serum free medium and starved for 24 h in DMEM containing 0.5% calf serum. Cells were treated with various concentrations of FGF-1 and FGF-4 for 10 min at 378C. Cells were then lysed, subjected to immunoprecipitation and samples were run on SDS ± PAGE. After electrotransfer onto nitrocellulose, ®lters were incubated with polyclonal or monoclonal (4G10) anti-phospho-tyrosine antisera, followed by horseradish peroxidase-conjugated secondary antibodies, and developed by enhanced chemiluminescence according to the manufacturer's instruction (ECL, Amersham). In vivo receptor phosphorylation in transiently transfected cells was also performed as described above.
Cell dierentiation and indirect immuno¯uorescence
Stably transfected C2-7 cells were plated on glass coverslips placed into 24 well plates at a density of 2.5610 4 cells/well. Dierentiation was induced with DMEM containing 0.5% horse serum. After 72 ± 96 h, cells were ®xed with 3.7% formaldelhyde for 30 min at room temperature, and stained with Giemsa, or permeabilized in 0.5% Triton X-100-PBS for 5 min on ice. Anti skeletal myosin antibody was applied in PBS (1:200 diluton, M-4276 Sigma) for 1 h at room temperature. Coverslips were washed four times with PBS, incubated with¯uorescen conjugated goat anti mouse IgG for 1 h, washed with PBS, mounted and examined under epifluorescence.
Binding assays
Cells were plated at a density of 2610 5 /3 cm dish for 24 h in DMEM containing 10% calf serum, washed once in cold binding medium (DMEM supplemented with 25 mM HEPES (pH 7.5) and 0.15% gelatin), and incubated for 2 h at 48C with varying concentrations of [
125 I]FGF-1 (500 c.p.m./fmol) and 25 mg/ml heparin in binding medium. The binding medium was collected, and cells were washed twice with PBS (pH 7.5) containing 0.1 M NaCl. High anity binding was determined by washing the cells twice with 1 ml of cold acid wash (20 mM sodium acetate (pH4.0), 2 M NaCl) and counting in a g counter. Nonspeci®c binding for each concentration of FGF-1 was determined in the presence of 100-fold excess cold FGF-1 in parallel plates.
